RE:TauRx Phase 3 Trial Results The Conference takes place in London, UK.
TauRX will present at 12:45pm (London time) (7:45am EST) on Thursday June 9th
"12-months safety and efficacy data of the Phase 3 LUCIDITY trial, a randomized, double-blind, placebo-controlled, 12-month, safety, and efficacy study of hydromethylthionine mesylate (HMTM) 16 mg/day oral tablet monotherapy in patients with MCI due to probable AD or mild-moderate AD. LUCIDITY will continue to run for a further 12 months open label phase during which all study patients have access to the 16mg/day oral dose, with expected end results May 2023.
This session will share available information and includes an independent panel discussion on the potential impact of the trial outcome for people with dementia across the spectrum of mild cognitive impairment (MCI) to moderate Alzheimer’s disease, and the future direction of AD research."
LINK to programme